Sugi Predict

Sugi Predict / Targets / PCSK6

PCSK6

Proprotein convertase subtilisin/kexin type 6 · P29122 · PCSK6 on Sugi Atlas →

377 patent compounds predicted against PCSK6, 163 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29384677 SCHEMBL29384677 0.63 1/20
SCHEMBL31238543 SCHEMBL31238543 0.56 1/20
SCHEMBL15896438 SCHEMBL15896438 0.55 1/20
SCHEMBL19558265 SCHEMBL19558265 0.55 1/20
SCHEMBL31151632 SCHEMBL31151632 0.54 1/20
SCHEMBL29510589 SCHEMBL29510589 0.54 1/20
SCHEMBL29510727 SCHEMBL29510727 0.54 1/20
SCHEMBL29904521 SCHEMBL29904521 0.54 1/20
SCHEMBL29823488 SCHEMBL29823488 0.54 1/20
SCHEMBL30207102 SCHEMBL30207102 0.53 1/20
SCHEMBL31154645 SCHEMBL31154645 0.53 1/20
SCHEMBL31114998 SCHEMBL31114998 0.53 1/20
SCHEMBL3035812 SCHEMBL3035812 0.52 1/20
SCHEMBL29577402 SCHEMBL29577402 0.52 1/20
SCHEMBL30436298 SCHEMBL30436298 0.52 1/20
SCHEMBL31024301 SCHEMBL31024301 0.52 1/20
Anoplin Anoplin (SCHEMBL29578322) 0.52 1/20
SCHEMBL29717149 SCHEMBL29717149 0.52 1/20
SCHEMBL13811923 SCHEMBL13811923 0.52 1/20
SCHEMBL20951744 SCHEMBL20951744 0.52 1/20

Clinical trials — most relevant to PCSK6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lipid Management in Renal Transplant Recipients Using Evolocumab. PHASE4COMPLETED
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI PHASE4ACTIVE_NOT_RECRUITING
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke PHASE4NOT_YET_RECRUITING
Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients PHASE4ACTIVE_NOT_RECRUITING
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients PHASE3COMPLETED
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia PHASE3UNKNOWN
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) PHASE3COMPLETED
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) PHASE3COMPLETED
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity PHASE3COMPLETED
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH PHASE3ACTIVE_NOT_RECRUITING
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy PHASE2/PHASE3NOT_YET_RECRUITING
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event PHASE3ACTIVE_NOT_RECRUITING
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) PHASE2RECRUITING
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab® nanUNKNOWN
Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance nanCOMPLETED
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease nanRECRUITING
A Registration Study for Familial Hypercholesterolemia in Taiwan nanUNKNOWN
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom nanRECRUITING
The Danish Familial Hypercholesterolemia Organized Coronary Screening Trial nanACTIVE_NOT_RECRUITING
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids nanRECRUITING
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment nanUNKNOWN
To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy nanUNKNOWN
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States nanCOMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH) nanWITHDRAWN
Kinetic Study of Lp(a) and PCSK9 in Humans nanCOMPLETED
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease nanRECRUITING
Development of a Prognostic Tool for the Stratification of Cardiovascular Risk in Patients With Ischemic Stroke nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PCSK6 binder may also engage these)

ProteinNameSimilarity
Q63415 — 1.000 Q63415 →
Q28193 — 0.992 Q28193 →
FURIN Furin 0.990 landscape →
Q04592 — 0.990 Q04592 →
P23377 — 0.990 P23377 →
P41413 — 0.988 P41413 →
P23188 — 0.987 P23188 →
Q92824 — 0.986 Q92824 →
P28841 — 0.986 P28841 →
P21661 — 0.985 P21661 →
Q5R544 — 0.985 Q5R544 →
Q95220 — 0.984 Q95220 →
P29119 — 0.984 P29119 →
Q4R577 — 0.984 Q4R577 →
Q9GLR0 — 0.984 Q9GLR0 →
P35952 — 0.984 P35952 →
Q5R1W3 — 0.983 Q5R1W3 →
Q9VBC7 — 0.983 Q9VBC7 →
LOXL3 Lysyl oxidase homolog 3 0.983 landscape →
P16519 — 0.983 P16519 →
Q9Z175 — 0.983 Q9Z175 →
MMP24 Matrix metalloproteinase-24 0.983 landscape →
Q3U435 — 0.983 Q3U435 →
Q5G265 — 0.982 Q5G265 →
D3ZTE0 — 0.982 D3ZTE0 →
Q8CG16 — 0.982 Q8CG16 →
P01131 — 0.982 P01131 →
Q78EH2 — 0.982 Q78EH2 →
P35546 — 0.982 P35546 →
P53690 — 0.982 P53690 →